Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTZP4KZK)

• DOT Name: Casein kinase II subunit alpha 3 (CSNK2A3)
• Synonyms: CK II alpha 3; EC 2.7.11.1; Casein kinase II alpha 1 polypeptide pseudogene
• Gene Name: CSNK2A3
• Related Disease:
  leukaemia
  Leukemia
  Lung cancer
  Non-small-cell lung cancer
  Lung carcinoma
• UniProt ID: CSK23_HUMAN
• EC Number: 2.7.11.1
• Pfam ID: PF00069
• Sequence:
  MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINIT
  NNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTD
  FKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAE
  FYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWRLGCMLASMIFRKEPFFHGRDNYD
  QLVRIAKFLGTEDLYGYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDF
  LDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANVMSGISSVPT
  PSPLGPLAGSPVIAAANPLGMPVPAATGAQQ
• Function: Probable catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Amplification-dependent oncogene; promotes cell proliferation and tumorigenesis by down-regulating expression of the tumor suppressor protein, PML. May play a role in the pathogenesis of the lung cancer development and progression.
• Tissue Specificity: Detected in blood platelets and megakaryocyte cell lines. Poorly expressed in lung. Highly expressed in lung tumor tissues.
• KEGG Pathway:
  Ribosome biogenesis in eukaryotes (hsa03008)
  NF-kappa B sig.ling pathway (hsa04064)
  Mitophagy - animal (hsa04137)
  Wnt sig.ling pathway (hsa04310)
  Adherens junction (hsa04520)
  Alzheimer disease (hsa05010)
  Prion disease (hsa05020)
  Pathways of neurodegeneration - multiple diseases (hsa05022)
  Measles (hsa05162)
  PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235)

Molecular Interaction Atlas (MIA) of This DOT

5 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
leukaemia	DISS7D1V	Definitive	Altered Expression	[1]
Leukemia	DISNAKFL	Definitive	Altered Expression	[1]
Lung cancer	DISCM4YA	Definitive	Genetic Variation	[1]
Non-small-cell lung cancer	DIS5Y6R9	Definitive	Altered Expression	[1]
Lung carcinoma	DISTR26C	Strong	Genetic Variation	[1]

3 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Cisplatin	DMRHGI9	Approved	Cisplatin increases the expression of Casein kinase II subunit alpha 3 (CSNK2A3).	[2]
Temozolomide	DMKECZD	Approved	Temozolomide increases the expression of Casein kinase II subunit alpha 3 (CSNK2A3).	[4]
Milchsaure	DM462BT	Investigative	Milchsaure affects the expression of Casein kinase II subunit alpha 3 (CSNK2A3).	[5]

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Quercetin	DM3NC4M	Approved	Quercetin affects the binding of Casein kinase II subunit alpha 3 (CSNK2A3).	[3]

References

• [1] Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.PLoS One. 2010 Jul 2;5(7):e11418. doi: 10.1371/journal.pone.0011418.
• [2] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [3] Biotinylated quercetin as an intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins. Bioorg Med Chem. 2011 Aug 15;19(16):4710-20. doi: 10.1016/j.bmc.2011.07.005. Epub 2011 Jul 13.
• [4] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [5] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.